ImaginAb, a developer of antibody fragments for diagnostic imaging, is set to offer radiolabeling services for antibodies made up of proteins, peptides and other macromolecules.
The company said this initiative is to broaden the range of product and service offerings to the biopharma and research community and is synergistic with existing activities in custom antibody fragment engineering.
ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products.
ImaginAb president and COO Jenny Keppler said in response to demand for their radiochemistry and, in particular antibody labeling expertise, they have decided to make this capability a standard service offering as part of their recent LA facility expansion.